Epizyme Inc
F:EPE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Epizyme Inc
Intangible Assets
Epizyme Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Epizyme Inc
F:EPE
|
Intangible Assets
$40.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$66.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
46%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$20.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$28.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$831.6m
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Epizyme Inc
Glance View
Nestled in the bustling world of biotechnology, Epizyme Inc. emerged as a dynamic player within the realm of epigenetic medicine. The company carved a niche for itself by focusing on the development and commercialization of novel therapeutics that target the epigenetic regulation of gene expression. Founded with a vision to harness the power of small molecules to modulate the proteins responsible for reading and interpreting the epigenetic code, Epizyme strives to innovate therapies that can treat patients with serious unmet medical conditions, particularly in oncology. Its flagship product, Tazemetostat, received FDA approval for the treatment of certain types of lymphoma and soft tissue sarcoma. This marked a significant milestone for the company, confirming its ability to transform complex biological science into tangible, market-ready solutions. With a strategic approach centered on precision medicine, Epizyme monetizes its innovations primarily through direct sales, partnerships, and licensing agreements. The company’s revenue streams are buoyed by its collaborations with other biotechnology and pharmaceutical companies keen on leveraging Epizyme’s specialized expertise to advance their own drug development programs. Moreover, by advancing a robust pipeline of epigenetic therapies that span a variety of therapeutic areas, Epizyme positions itself to capture a growing share of the biotechnology market. Intellectual property and sophisticated R&D capabilities underpin its business model, enabling the company not only to produce groundbreaking therapies but also to secure significant market opportunities in an increasingly competitive landscape.
See Also
What is Epizyme Inc's Intangible Assets?
Intangible Assets
40.8m
USD
Based on the financial report for Jun 30, 2022, Epizyme Inc's Intangible Assets amounts to 40.8m USD.
What is Epizyme Inc's Intangible Assets growth rate?
Intangible Assets CAGR 1Y
-9%
Over the last year, the Intangible Assets growth was -9%.
You don't have any saved screeners yet
